Companies Unite to Advance Regulatory Landscape of Abuse Potential Assessment

Posted 01 September 2011 | By Beatriz Rocha Heddie Martynowicz Rol W. Usher Andrew Friedman Jonathon Parker Richard Fanelli Suzanne Thornton-Jones Cynthia Arons Mark Ammann 

The US Food and Drug Administration (FDA) is collaborating with private and public stakeholders in an effort to address critical public health needs and to bridge scientific gaps.1 One of these collaborations focuses on abuse potential and involves three key groups: the Controlled Substance Staff (CSS) of FDA, the Pharmaceutical Research and Manufacturers of America (PhRMA) and the Cross Company Abuse Liability Consortium (CCALC).

Regulatory Focus newsletters

All the biggest regulatory news and happenings.

Subscribe